Refractory Acute Myeloid Leukemia (AML) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Refractory Acute Myeloid Leukemia (AML) affects about 50% of all patients who achieve remission after initial treatment. With a long-term disease-free survival of only approximately 30 to 40% after standard chemotherapy and a paucity of treatment options besides the standard cytarabine and anthracyclines, disease persistence or recurrence occurs in most patients with AML. Outcomes for patients with relapsed or refractory AML are poor, with overall survival (OS) estimated at no more than 10% at three years. The prognosis for relapsed acute myeloid leukemia (AML) is unfavorable, and managing the disease presents significant challenges. Among patients who achieve complete remission after relapse, allogeneic hematopoietic cell transplantation (allo-HCT) remains the most effective treatment option. Relapse after allo-HCT remains a major obstacle, with a 1-year post-relapse OS of ~20%. Although several therapeutic options are available for relapsed AML after transplantation, only a minority of patients survive long-term.
Thelansis’s “Refractory Acute Myeloid Leukemia (AML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Refractory Acute Myeloid Leukemia (AML) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Refractory Acute Myeloid Leukemia (AML) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Refractory Acute Myeloid Leukemia (AML) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Tags: Refractory Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML) market outlook, Refractory Acute Myeloid Leukemia (AML) competitive landscape, Refractory Acute Myeloid Leukemia (AML) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)
